VC, infectious diseases, Life Sciences

Pulmatrix Inhales $3M Financing

Ryan McBride 3/13/09

Pulmatrix, a Lexington, MA-based developer of aerosol drugs intended to treat and prevent the spread of respiratory ailments, has raised $3 million in a financing, Mass High Tech reports, citing a regulatory filing. A company spokeswoman says the financing is a bridge round in anticipation of a larger financing, but the firm isn’t commenting on the details of the deal. The six-year-old firm’s previous backers include Waltham, MA, venture firms 5AM Ventures and Polaris Venture Partners. Luke wrote about Pulmatrix in September when it emerged from stealth mode.

Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com, or follow him on Twitter at http://twitter.com/Ryan_McBride.